Skip to content

13F-HR filed by Palo Alto Investors LP

Palo Alto Investors LP filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 32 holding rows worth $1,264,742,000.

Accession
0001306923-22-000016
Filed
2022-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 32 entries on the cover page, a total value of $1,264,742,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,264,742,000 with VALUE read as thousands by filing date, 13F file number 028-11013. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOMARIN PHARMACEUTICAL INC09061G101COM1,976,265$167,528,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock633,534$132,649,000thousands by filing date
INSMED INC COM PAR $.01457669307Stock5,840,398$125,802,000thousands by filing date
ABIOMED INC003654100COM490,754$120,559,000thousands by filing date
REVANCE THERAPEUTICS INC761330109COM4,405,039$118,936,000thousands by filing date
AMICUS THERAPEUTICS INC03152W109COM9,847,774$102,811,000thousands by filing date
PROTHENA CORP PLC SHSG72800108Stock1,649,777$100,026,000thousands by filing date
BIOGEN INC COM09062X103Stock360,981$96,382,000thousands by filing date
STAAR SURGICAL CO COM PAR $0.01852312305Stock1,096,882$77,385,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM851,409$33,341,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM5,621,533$30,694,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM1,678,196$27,455,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM2,166,156$21,402,000thousands by filing date
GOSSAMER BIO INC COM38341P102Stock1,750,651$20,973,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM612,600$14,721,000thousands by filing date
ALKERMES PLCG01767105SHS603,400$13,474,000thousands by filing date
ANAPTYSBIO INC032724106COM431,024$10,995,000thousands by filing date
ALIGN TECHNOLOGY INC COM016255101Stock44,305$9,176,000thousands by filing date
EHEALTH INC28238P109COM1,977,993$7,734,000thousands by filing date
GRITSTONE BIO INC39868T105COM2,330,504$5,989,000thousands by filing date
KEZAR LIFE SCIENCES INC49372L100COM656,200$5,650,000thousands by filing date
CYTOKINETICS INC23282W605COM NEW111,717$5,413,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM4,473,967$5,324,000thousands by filing date
TRAVERE THERAPEUTICS INC89422G107COM166,069$4,092,000thousands by filing date
PROVENTION BIO INC74374N102COM390,800$1,759,000thousands by filing date
MIRUM PHARMACEUTICALS INC604749101COM64,700$1,359,000thousands by filing date
ALIMERA SCIENCES INC016259202COM200,919$1,021,000thousands by filing date
ALDEYRA THERAPEUTICS INC01438T106COM160,800$859,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock432,300$610,000thousands by filing date
TACTILE SYSTEMS TECHNOLOGY I87357P100COMMON STOCK27,100$211,000thousands by filing date
MARINUS PHARMACEUTICALS INC56854Q200COM NEW31,330$208,000thousands by filing date
UROGEN PHARMA LTDM96088105COMMON STOCK24,500$204,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001306923-22-000016this filing2022-11-14acceptance time not in the bulk data set